Critical Diagnostics announced today the launch of ST2online.com, a free online resource designed to deliver clinical and research information specific to ST2--a cardiac biomarker that, in over 100 clinical trials has shown to be the most prognostic biomarker for improving the management of heart failure.

"We are embarking on yet another milestone in advancing medicine with this web-based resource for ST2," notes David Geliebter, CEO and Chairman of Critical Diagnostics. "The goal is to facilitate the education of clinicians, which will in turn equip them with the information they need to practice evidenced-based medicine that improves patient care."

Initially, ST2online.com will house a collection of interviews from world-renowned cardiologists, a review of key publications, as well as an extensive searchable bibliography relating to ST2 and its potential utility in the spectrum of heart disease. Future plans include the integration of a clinical forum where clinicians will have the ability to interact and interface with experts to discuss topics relevant to their clinical practice.

To obtain access to this exclusive web-based resource, visit www.ST2online.com and register.

About ST2

ST2 is a soluble protein expressed by the heart in response to disease or injury. It is reflective of ventricular remodeling and cardiac fibrosis associated with heart failure. ST2 is not adversely affected by confounding factors such as age, body mass index and impaired renal function. Unlike many other cardiac biomarkers, ST2 levels change quickly in response to changes in the patient's condition--thus helping physicians make informed decisions on an appropriate course of action to take and, if needed, to quickly adjust treatment. All this makes ST2 an ideal serial biomarker for monitoring and treating heart failure patients.

The 2013 ACC/AHA Guideline For The Management of Heart Failure, recognizes ST2 as "not only predictive of hospitalization and death in patients with HF but also additive to natriuretic peptide levels in [its] prognostic value."

The Presage® ST2 Assay from Critical Diagnostics is the only commercially available ST2 biomarker in the world. The Presage ST2 Assay has been CE Marked and cleared by the U.S. FDA for use as in the risk stratification of chronic heart failure patients.

About Critical Diagnostics

Founded in 2004, Critical Diagnostics (www.criticaldiagnostics.com) develops novel biomarkers to help physicians optimize patient care in cardiovascular diseases, while containing healthcare costs. Critical Diagnostics has distribution partners for its Presage ST2 Assay in 45 countries, covering two-thirds of the world's population.

For More Information:
Critical Diagnostics
Dennis Dalangin, +1-877-700-1250
VP Marketing
ddalangin@criticaldiagnostics.com